Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

daprodustat

- PMLiVE

Roche’s injectable PD-L1 inhibitor granted FDA approval for multiple cancer types

Tecentriq Hybreza can be injected subcutaneously over approximately seven minutes

- PMLiVE

GSK’s mRNA seasonal flu vaccine shows promise in younger and older adults

The company said it will now progress the programme into late-stage clinical development

- PMLiVE

Johnson & Johnson’s IL-23 inhibitor Tremfya granted FDA approval for ulcerative colitis

The inflammatory bowel disease is estimated to affect more than one million people in the US

- PMLiVE

GSK shares positive phase 3 results for long-acting biologic in severe asthma

Depemokimab is designed to allow for six-month dosing intervals for patients with the lung condition

- PMLiVE

FDA grants full approval to Travere’s Filspari for rare kidney disease IgA nephropathy

The regulator’s decision expands the drug’s indication to cover all patients who are at risk of disease progression

- PMLiVE

GSK announces positive late-stage results for IL-5 inhibitor Nucala in COPD

The chronic respiratory disease affects more than 300 million people globally

- PMLiVE

Novavax’s JN.1-adapted COVID-19 vaccine granted FDA emergency use authorisation

JN.1 only accounts for 0.2% of cases across the country but is the ‘parent strain’ of currently circulating variants

- PMLiVE

GSK’s RSV vaccine Arexvy approved by EC for use in adults aged 50 to 59 years

An estimated 20 million adults in this age population are at an increased risk of severe RSV outcomes

- PMLiVE

FDA approves updated COVID-19 vaccines to better protect against current variants

Adapted vaccines from Pfizer/BioNTech and Moderna have been authorised for individuals aged six months and older

- PMLiVE

Incyte and Syndax’s Niktimvo granted FDA approval in chronic graft versus host disease

Approximately 42% of patients receiving an allogeneic stem cell transplant will develop the condition

- PMLiVE

FDA approves Galderma’s IL-31 inhibitor Nemluvio to treat prurigo nodularis in adults

The chronic skin condition is estimated to affect up to 181,000 people in the US

- PMLiVE

J&J’s Rybrevant/Lazcluze combination approved by FDA as first-line lung cancer treatment

Non-small cell lung cancer accounts for up to 85% of all lung cancer cases

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links